Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAA2 | P54646 | 1/20 | 0.68 |
| ▸ | RXRA | P19793 | 2/20 | 0.56 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
| ▸ | HMGCR | P04035 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TNKS | O95271 | 1/20 | 0.40 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.40 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14749820 | 0.84 | PRKAA2 (0.77) | PRKAA2RXRANR1I2NR4A2PDE4D | |
| SCHEMBL27950491 | 0.83 | PRKAA2 (0.68) | PRKAA2RXRANR1I2NR4A2PDE4D | |
| SCHEMBL27512912 | 0.83 | PRKAA2 (0.68) | PRKAA2RXRANR1I2NR4A2PDE4D | |
| Methane SCHEMBL27947407 | 0.83 | PRKAA2 (0.72) | PRKAA2RXRANR1I2NR4A2PDE4D | |
| SCHEMBL28803542 | 0.83 | PRKAA2 (0.68) | PRKAA2RXRANR1I2NR4A2PDE4D | |
| SCHEMBL14114892 | 0.83 | PRKAA2 (0.68) | PRKAA2RXRANR1I2NR4A2PDE4D | |
| SCHEMBL15481464 | 0.83 | PRKAA2 (0.64) | PRKAA2RXRANR1I2NR4A2PDE4D | |
| SCHEMBL12102947 | 0.83 | PRKAA2 (0.64) | PRKAA2RXRANR1I2NR4A2PDE4D | |
| SCHEMBL6747781 | 0.83 | PRKAA2 (0.64) | PRKAA2RXRANR1I2NR4A2PDE4D | |
| SCHEMBL27953854 | 0.83 | PRKAA2 (0.64) | PRKAA2RXRANR1I2NR4A2PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010089770-A2 | IMPROVED PROCESS FOR THE PREPARATION OF HIGHLY PURE (3R,5S)-7-[2-CYCLOPROPYL-4-(4-FLUOROPHENYL) QUINOLIN-3-YL]-3,5-DIHYDROXY-6(E)-HEPTENOIC ACID AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | MSN LABORATORIES LIMITED (IN) | 2010-08-12 | — | — | WO | claimed |
| EP-3333155-B1 | METHOD FOR PRODUCING PITAVASTATIN CALCIUM | API CORP (JP) | 2023-05-24 | — | — | EP | disclosed |
| US-11344548-B2 | Analogs of 3,5-dihydroxypentanoate for bone formation | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2022-05-31 | — | — | US | disclosed |
| US-20210322411-A1 | ANALOGS OF 3,5-DIHYDROXYPENTANOATE FOR BONE FORMATION | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2021-10-21 | — | — | US | disclosed |
| US-20190152916-A1 | CRYSTAL FORM OF QUINOLINE COMPOUND AND PROCESS FOR ITS PRODUCTION | NISSAN CHEMICAL CORPORATION (JP) | 2019-05-23 | — | — | US | disclosed |
| EP-3333155-A1 | METHOD FOR PRODUCING PITAVASTATIN CALCIUM | API Corporation (JP) | 2018-06-13 | — | — | EP | disclosed |
| EP-2247739-B1 | ((2S,4R)-4,6-DIHYDROXYTETRAHYDRO-2H-PYRAN-2-YL)METHYL CARBOXYLATE AND PROCESS FOR ITS PRODUCTION EMPLOYING A 2-DEOXYRIBOSE-5-PHOSPHATE ALDOLASE (DERA) | LEK PHARMACEUTICALS (SI) | 2018-05-16 | — | — | EP | disclosed |
| US-9932361-B2 | Convenient process for the preparation of statins | F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2018-04-03 | — | — | US | disclosed |
| EP-2655650-B1 | ENZYMATIC SYNTHESIS OF ACTIVE PHARMACEUTICAL INGREDIENT AND INTERMEDIATES THEREOF | LEK PHARMACEUTICALS (SI) | 2017-12-20 | — | — | EP | disclosed |
| US-20170226061-A1 | CRYSTAL FORM OF QUINOLINE COMPOUND AND PROCESS FOR ITS PRODUCTION | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-08-10 | — | — | US | disclosed |
| US-20080255170-A1 | Process for the Synthesis of Rosuvastatin Calcium | LEK PHARMACEUTICALS D.D (SI) | 2008-10-16 | — | — | US | disclosed |
| WO-2008119810-A2 | PROCESSES FOR THE PREPARATION OF STATINS, PARTICULARLY ROSUVASTATIN, AND INTERMEDIATES FOR THE PREPARATION THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2008-10-09 | — | — | WO | disclosed |
| EP-1978020-A1 | Processes for the preparation of statins, particularly rosuvastatin, and intermediates for the preparation thereof | LEK Pharmaceuticals D.D. (SI) | 2008-10-08 | — | — | EP | disclosed |
| WO-2008044243-A2 | NOVEL PROCESS FOR THE PREPARATION OF STATINS AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | SATYANARAYANA REDDY MANNE (IN) | 2008-04-17 | — | — | WO | disclosed |
| WO-2007125547-A2 | NOVEL PROCESS FOR STATINS AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | SATYANARAYANA REDDY MANNE (IN) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007125547-A2 | NOVEL PROCESS FOR STATINS AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | SATYANARAYANA REDDY MANNE (IN) | 2007-11-08 | — | — | WO | disclosed |
| EP-1825848-A2 | Stable pharmaceutical compositions comprising an HMG-CoA reductase inhibitor | STADA ARZNEIMITTEL AG (DE) | 2007-08-29 | — | — | EP | disclosed |
| EP-1818050-A1 | Stable pharmaceutical compositions comprising a HMG-CoA reductase inhibitor | STADA ARZNEIMITTEL AG (DE) | 2007-08-15 | — | — | EP | disclosed |
| WO-2007039287-A1 | PROCESS FOR THE SYNTHESIS OF HMG-CoA REDUCTASE INHIBITORS | LEK PHARMACEUTICALS D.D. (SI) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007017117-A1 | PROCESS FOR THE SYNTHESIS OF ROSUVASTATIN CALCIUM | LEK PHARMACEUTICALS D.D. (SI) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152916-A1 | CRYSTAL FORM OF QUINOLINE COMPOUND AND PROCESS FOR ITS PRODUCTION | VAT1, CACNA1A, VMP1 | PRKAA2 2515/4885RXRA 3755/4885NR1I2 3925/4885 |
| US-11344548-B2 | Analogs of 3,5-dihydroxypentanoate for bone formation | CYP24A1, CYP27B1, CYP2R1 | PRKAA2 2405/4885RXRA 197/4885NR1I2 1351/4885 |
| US-20080255170-A1 | Process for the Synthesis of Rosuvastatin Calcium | HMGCR, ME1, COASY | PRKAA2 1233/4885RXRA 3882/4885NR1I2 942/4885 |
| US-20170226061-A1 | CRYSTAL FORM OF QUINOLINE COMPOUND AND PROCESS FOR ITS PRODUCTION | VAT1, CACNA1A, VMP1 | PRKAA2 2496/4885RXRA 3742/4885NR1I2 3919/4885 |
| US-20210322411-A1 | ANALOGS OF 3,5-DIHYDROXYPENTANOATE FOR BONE FORMATION | CYP24A1, CYP27B1, CYP2R1 | PRKAA2 2405/4885RXRA 197/4885NR1I2 1351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.